Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. reports developments for leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor. The company is a clinical-stage oncology issuer focused on CCR5 biology in difficult-to-treat cancers, including metastatic triple-negative breast cancer and metastatic colorectal cancer.
Recurring news includes clinical and translational data presentations, Phase 2 colorectal cancer study updates, expanded access activity for triple-negative breast cancer, and preclinical work in glioblastoma. Company updates also cover financing actions used to support leronlimab development and corporate webcasts addressing scientific, operational, clinical, and financial progress.
CytoDyn Inc. (OTC.QB: CYDY) announced an upcoming investment community webcast on October 20, 2020, to discuss recommendations from the Data Safety Monitoring Committee (DSMC) based on an interim analysis of the Phase 2b/3 trial for severe-to-critical COVID-19. Key management, including President Nader Pourhassan, will provide insights into a potential regulatory path forward. The webcast will feature a presentation followed by a Q&A session. Access will be through CytoDyn's corporate website, with replay available for 30 days.
CytoDyn (OTC.QB: CYDY) announced the appointment of Chiral Pharma Corporation to register leronlimab (PRO 140) for potential COVID-19 treatment approval in the Philippines. The company is conducting Phase 2 and Phase 3 trials for COVID-19, with interim results expected mid-October. Leronlimab has received Fast Track designation for indications in HIV and metastatic triple-negative breast cancer. The drug has shown promising results in multiple clinical trials, significantly reducing HIV viral load and tumor metastasis.
CytoDyn Inc. (OTC.QB: CYDY) announces its 2020 Virtual Annual Meeting of Stockholders, scheduled for September 30, 2020, at 9:30 am PT. Due to health concerns from the coronavirus pandemic, in-person attendance is not allowed. Stockholders can log in to participate via the provided webcast link, and questions can be submitted online during the meeting with the passcode CYDY2020. Dr. Nader Pourhassan, CEO, will present a company overview post-business session, with materials available on the company website.